Clinical Trial: Efficacy Evaluation and Patient Selection for High-Risk Unresectable Hepatocellular Carcinoma Treated with TACE Combined with Targeted and Immunotherapy: A Multicenter Real-World Retrospective Study (China)

Posted On: 2026-09-28

China, Sept. 28 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy Evaluation and Patient Selection for High-Risk Unresectable Hepatocellular Carcinoma Treated with TACE Combined with Targeted and Immunotherapy: A Multicenter Real-World Retrospective Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133413

Registration Time: 2026/09/26

Type: Observational study

Primary Sponsor: The First Affiliated Hospital of Air Force Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=338770

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy Evaluation and Patient Selection for High-Risk Unresectable Hepatocellular Carcinoma Treated with TACE Combined with Targeted and Immunotherapy: A Multicenter Real-World Retrospective Study (China)